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Background: Use of atypical antipsychotics (AA) in combination with an antidepressant is recommended as an
augmentation strategy for patients with depression. However, there is a paucity of data comparing aripiprazole and
other AAs in terms of patient reported outcomes. Therefore, the objective of this study was to examine the levels
of HRQoL and health utility scores in patients with depression using aripiprazole compared with patients using
olanzapine, quetiapine, risperidone and ziprasidone.
Methods: Data were obtained from the 2009, 2010, and 2011 National Health and Wellness Survey (NHWS),
a cross-sectional, internet-based survey that is representative of the adult US population. Only those patients who
reported being diagnosed with depression and taking an antidepressant and an atypical antipsychotic for
depression were included. Patients taking an atypical antipsychotic for less than 2 months or who reported being
diagnosed with bipolar disorder or schizophrenia were excluded. Patients taking aripiprazole were compared with
patients taking other atypical antipsychotics. Health-related quality of life (HRQoL) and health utilities were assessed
using the Short Form 12-item (SF-12) health survey. Differences between groups were analyzed using General
Linear Models (GLM) controlling for demographic and health characteristics.
Results: Overall sample size was 426 with 59.9% taking aripiprazole (n = 255) and 40.1% (n = 171) taking another
atypical antipsychotic (olanzapine (n = 19), quetiapine (n = 127), risperidone (n = 14) or ziprasidone (n = 11)). Of the
SF-12 domains, mean mental component summary (MCS) score (p = .018), bodily pain (p = .047), general health
(p = .009) and emotional role limitations (p = .009) were found to be significantly higher in aripiprazole users
indicating better HRQoL compared to other atypical antipsychotics. After controlling for demographic and health
characteristics, patients taking aripiprazole reported significantly higher mean mental SF-12 component summary
(34.10 vs. 31.43, p = .018), bodily pain (55.19 vs. 49.05, p = .047), general health (50.05 vs. 43.07, p = .009), emotional
role limitations (49.44 vs. 41.83, p = .009), and SF-6D utility scores (0.59 vs. 0.56, p = .042).
Conclusions: Comparison of patients taking aripiprazole with a cohort of patients using another AA for depression
demonstrated that aripiprazole was independently associated with better (both statistically and clinically) HRQoL
and health utilities.* Correspondence: marco.dibonaventura@kantarhealth.com
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Major depressive disorder (MDD) is a recurrent mental
illness with a lifetime prevalence of approximately 16%
in the United States (US) [1]. Marked by depressed
mood and the inability to experience pleasure from ac-
tivities, MDD is associated with premature mortality due
to suicide and comorbidities such as cardiovascular and
respiratory disease [2]. Donohue & Pincus (2007) esti-
mated the healthcare costs of depression in the US were
$26 billion per year and indirect costs (due to lost prod-
uctivity in the workplace) were $52 billion per year [3].
Kessler et al. (2003) found the majority of patients who
reported experiencing MDD in the past 12 months also
experienced moderate to severe role limitations at home
or work, or in their relationships (as measured by the
Sheehan Disability scale) [1]. By 2020, it is estimated de-
pressive disorders will rank as the second most costly
group of diseases globally, in terms of disability adjusted
years lost [3].
Patients with depression also report significant impair-
ments in health-related quality of life (HRQoL). Results
from the Medical Outcomes Study showed patients with
depression had mental component summary (MCS)
scores approximately 1 standard deviation below the
general US population [4]. Remission of symptoms has
been found to lead to improved quality of life [4].
Although it is important to note that treating depres-
sion is generally cost-effective, less than 1 out of 3
patients with clinical depression achieve remission after
completing a course of first-line therapy [5]. In fact, as
widely cited from the STAR*D study, 2 out of 5 patients
with clinical depression will not respond to depression
treatment, even after they have completed a course of
fourth-line therapy [5].
Because of inadequate response to treatment, newer
molecules such as atypical antipsychotics, which were
not included in the STAR*D study, have been increas-
ingly used in clinical practice. A number of randomized
clinical trials have demonstrated the beneficial effects
of olanzapine, quetiapine, risperidone and aripiprazole
[6-8] as augmentation to current antidepressants. Indeed,
a recent article by the World Psychiatric Association sug-
gests that the best evidence for antidepressant augmenta-
tion resides with atypical antipsychotics [9]. However,
literature reviews by Chen et al. (2011) and Pae et al.
(2011) produced no direct head-to-head comparisons of
atypical antipsychotics as augmentation treatments for
MDD and noted the need for pharmacoeconomic com-
parisons of atypical antipsychotics [7,10]. Therefore, the
objective of this study is, in a real world setting, to exam-
ine the levels of HRQoL and health utility scores in
patients with depression using aripiprazole compared
with patients using olanzapine, quetiapine, risperidone
and ziprasidone.Methods
Data source
This study used data from the 2009, 2010, and 2011 US
National Health and Wellness Survey (NHWS) data-
bases (Kantar Health, New York, NY). Data from these
surveys were collected between January 1, 2009 and
March 1, 2011. The NHWS is a cross-sectional,
internet-based survey of adults (aged 18+). Using a
stratified random sampling framework, potential respon-
dents are recruited through internet panels such that the
demographic composition of the NHWS is identical to
that of the general population, as measured by the US
Census. The reliability and validity of the NHWS, par-
ticularly as it relates to disease prevalence, has been
assessed in prior research [11-13]. These studies have
compared data collected from the NHWS and various
sources including the US Census Bureau’s Current
Population Survey, National Health Interview Survey,
National Health and Nutrition Examination Survey, and
the Medical Expenditure Panel Survey [11-13].
All participants of the NHWS agreed to participate in
the survey explicitly and were awarded nominal incen-
tives for their participation. The NHWS is approved
each year by Essex Institutional Review Board (Lebanon,
NJ). Of 1,157,205 who were invited to participate (from
January 1, 2009 to March 1, 2011), 250,849 responded
(21.68% response rate). Of those who responded,
175,000 (69.76%) met the study inclusion criteria (gave
informed consent and were aged 18 or over) and com-
pleted the survey.
Sample and procedure
Because the NHWS is fielded separately each year, it is
possible for a respondent to complete the survey in mul-
tiple years (e.g., the same respondent could have com-
pleted the NHWS in 2009 and 2010). In such cases, only
data from the most recent time point was kept and so a
total of 156,582 unique respondents were available.
Respondents were included in the study if they self-
reported a diagnosis of depression, were taking both an
antidepressant and an atypical antipsychotic medication
for their depression, were taking all their depression
medications for at least two months, and had complete
data on all study covariates. Respondents were excluded




Atypical antipsychotic use The primary independent
variable was a dichotomous variable comparing patients
taking aripiprazole and an antidepressant versus
patients taking another atypical antipsychotic (olanzapine,
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sant. For a complete list of antidepressants assessed in the
NHWS see Additional file 1.
Outcomes
Health-related quality of life (HRQoL) To measure
HRQoL, every respondent was asked to complete ver-
sion 2 of the Medical Outcomes Study Short Form 12
(SF-12) questionnaire [14]. The SF-12 is a generic meas-
ure of HRQoL, which assesses 8 health domains: phys-
ical functioning, physical role limitations, bodily pain,
general health perceptions, vitality, social functioning,
emotional role limitations, and mental health [14]. The
health domains are summarized by two summary scores:
the mental component summary (MCS) and physical
component summary (PCS), which are both standar-
dized to the US general population (Mean = 50, Standard
Deviation = 10). Both domain scores and summary
scores vary between 0 and 100; where higher scores indi-
cate greater health. Previous findings suggest the SF-12
instrument is sensitive to remission of depressive symp-
toms [15] and response to treatment among depression
patients [16]. Prior research has suggested that differ-
ences of 3 points in MCS and PCS are considered clinic-
ally meaningful [17].
Health utility The SF-6D, which is a preference-based
health utility index calculated from the SF-12 items, was
also reported [18]. Scores vary from 0.29-1.00, where
1.00 indicates perfect health. Previous findings indicate
the SF-6D is sensitive to remission of depressive symp-
toms, with 0.11 quality-adjusted life years gained over a
two year period with remission of symptoms [4]. Differ-
ences of 0.03 points in the SF-6D health utility are con-
sidered clinically meaningful [19].
Covariates
Demographic and health characteristics The following
information was assessed for all respondents: age, gen-
der, ethnicity/race, marital status, educational attain-
ment, household income, employment status, insurance
coverage, body mass index (BMI; measured as kg/m2),
exercise behavior, alcohol consumption, tobacco smok-
ing behavior, antidepressant use, type of prescriber, year
surveyed, time since diagnosis, and comorbidity burden
(using the Charlson Comorbidity Index) [20].
Statistical analyses
Bivariate analyses were conducted to describe and com-
pare the demographic and health characteristics of
patients being treated with aripiprazole versus other
atypical antipsychotics. For categorical variables, chi-square tests were used to determine significant differ-
ences, while t-tests were used for continuous variables.
Although our original intent was to compare aripipra-
zole with each individual atypical antipsychotic, this was
not possible due to small sample sizes of some of the
comparators. As a result, we focused primarily on the
comparison between aripiprazole and all other atypical
antipsychotics pooled together. These main analyses
compared those using aripiprazole with those using all
other atypical antipsychotics on all HRQoL and health
utility scores using t-tests. These differences were also
examined using General Linear Models (GLM), control-
ling for the covariates described above in order to miti-
gate the effect of selection bias (i.e., the systematic
reasons why a patient may be prescribed one atypical
medication over another which also may influence
HRQoL). Sub-analyses were also conducted to compare
users of aripiprazole with users of each individual atyp-
ical antipsychotic, though only the comparison with que-
tiapine had sufficient sample size for any meaningful
interpretation. Differences between the groups were first
made on an unadjusted level using t-tests. Subsequent
GLMs were then conducted to compare for group differ-
ences while controlling for the covariates mentioned
above.
Adjusted means, which provide the mean HRQoL
and utility scores when all covariates are set at the
sample mean, were obtained through a least-squares
algorithm for all GLMs (both in the main analysis and
the sub-analysis). All models controlled for the follow-
ing variables (reference variables are marked by an *):
age (in years), gender (female*, male), ethnicity/race
(non-Hispanic white*, non-Hispanic black, Hispanic,
other), marital status (married or living with a partner, all
else*), region (Northeast*, South, West, Midwest), house-
hold income (less than $25,000*, $25,000 to ≤ $50,000,
$50,000 to ≤ $75,000, $75,000 or more), insurance cover-
age (yes, no*), year surveyed (2009, 2010*, 2011), exercise
behavior (none in the past month*, 1 to 9 times in the
past month, 10 or more times in the past month), alcohol
consumption (none in the past month*, once or more in
the past month), BMI (underweight or normal weight*,
overweight, obese), comorbidity burden (Charlson
Comorbidity Index as a continuous variable), prescriber
type (psychiatrist, all else*), time since diagnosis (less
than 4 years*, 5 to 10 years, 11 or more years), selective
serotonin reuptake inhibitor use (yes, no*), selective nor-
epinephrine reuptake inhibitor (yes, no*), tricyclic anti-
depressant (yes, no*), other antidepressant use (yes, no*).
Sensitivity analyses were also conducted to assess the
robustness of the findings. Rather than entering all cov-
ariates simultaneously in the model, a series of hier-
archical multiple regressions were conducted to predict
all summary and domain HRQoL scores. For each
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In the first step, all demographic variables were entered
(age, gender, ethnicity, region, marital status, household
income, health insurance) into a multiple regression
model. For the second step, only the significant vari-
ables from the prior step as well as all health character-
istic information (smoking behavior, exercise behavior,
alcohol consumption, BMI, Charlson Comorbidity
Index, prescriber type, time since diagnosis, and con-
comitant treatments) were entered into a multiple re-
gression model. For the third step, all significant
variables from the prior step, as well as atypical anti-
psychotic use (aripiprazole versus other atypical anti-
psychotics) were entered into a general linear model.
Only the adjusted means from the third, and final
model, are reported. All analyses were conducted in
SAS v9.1 (Cary, NC) and the a priori cutoff for statis-
tical significance was p<.05.
Results
Sample characteristics
The study flowchart is shown in Figure 1. A total of
426 respondents met all study inclusion and exclusion
criteria. Of this group, 255 respondents reported taking
aripiprazole (59.86%) and 171 respondents reported
taking another atypical antipsychotic (40.14%). Of
those taking another atypical antipsychotic, 11.11%N=156,582 total unique NHWS 
respondents 
(January 2009 to March 2011)
n=26,298 reported a diagnosis of 
depression
n=22,822 did not report a of 
schizophrenia or a diagnosis of 
bipolar disorder
n=469 were using both an 
antidepressant and an atypical 
antipsychotic medication
n=459 reported using all their 
depression medications for at least 
2 months
n=426 reported
complete data for all study 
covariates
Figure 1 Study flowchart.were taking olanzapine (n = 19), 74.27% were taking
quetiapine (n = 127), 8.19% were taking risperidone
(n = 14), and 6.43% were taking ziprasidone (n = 11).
Compared to other atypical antipsychotic users,
respondents on aripiprazole were generally similar
demographically (see Table 1). However, respondents
taking aripiprazole were significantly more likely to be
from the South, retired, on disability, and more likely
to currently possess health insurance. These respon-
dents were also less likely to currently smoke (p<.05).
Respondents on aripiprazole were similar to other
atypical antipsychotic users with respect to their pre-
scribing physician and the years they had been diag-
nosed with depression (see Table 2). However,
aripiprazole users were significantly more likely to be
concomitantly treated with a selective norepinephrine
reuptake inhibitor (p<.05).
Main analysis: unadjusted differences between
respondents using aripiprazole and respondents using
other atypical antipsychotics
In bivariate (unadjusted) comparisons, respondents
using aripiprazole reported significantly higher mean
levels of mental component summary (MCS) scores
(34.26 vs. 32.09, p = .047, Cohen’s d = 0.20) when com-
pared with respondents using other atypical antipsycho-
tics, though no differences were observed on physicaln=130,284 did not report a 
diagnosis of depression
n=3,476 reported a diagnosis of 
schizophrenia or bipolar disorder
n=10 reported using at least one of 
their depression medications for 
less than 2 months
n=33 reported missing data on 
study covariates
n=22,353 were not using both an 
antidepressant and an atypical 
antipsychotic medication
Table 1 Demographic and health characteristic differences between patients taking aripiprazole or another atypical
antipsychotic to treat their depression
Aripiprazole (n = 255) Other atypical (n = 171)
Variable n % n % χ2 p
Male 110 43.14% 81 47.37% 0.74 0.391
Ethnicity
White 194 76.08% 129 75.44% 0.02 0.880
Black 31 12.16% 19 11.11% 0.11 0.741
Hispanic 14 5.49% 14 8.19% 1.13 0.289
Other 16 6.27% 9 5.26% 0.20 0.659
Married/living with partner 112 43.92% 68 39.77% 0.73 0.394
Region
Northeast 48 18.82% 36 21.05% 0.32 0.575
Midwest 57 22.35% 50 29.24% 2.50 0.115
South 98 38.43% 49 28.66% 4.48 0.035
West 52 20.39% 36 21.05% 0.03 0.869
Some college education (or higher) 194 76.08% 123 71.93% 0.91 0.342
Annual household income
<$25 K 98 38.43% 69 40.35% 0.16 0.692
$25 K to< $50 K 75 29.41% 53 30.99% 0.12 0.728
$50 K to< $75 K 45 17.65% 24 14.04% 1.02 0.313
$75 K or more 37 14.51% 25 14.62% 0.00 0.975
Employment status
Currently employed 95 37.25% 64 37.43% 0.00 0.971
Unemployed 55 21.57% 54 31.58% 5.18 0.023
On disability 20 7.84% 7 4.09% 2.73 0.099
Retired 41 16.08% 11 6.43% 10.49 0.001
On health insurance 230 90.20% 138 80.70% 7.13 0.008
Currently smoke 83 32.55% 78 45.61% 7.35 0.007
Exercise behavior
None in past month 128 50.20% 85 49.71% 0.01 0.921
One to nine times a month 66 25.88% 38 22.22% 0.76 0.385
Ten or more times a month 61 23.92% 48 28.07% 0.91 0.342
Currently drink alcohol 135 52.94% 106 61.99% 3.46 0.063
Body mass index
Normal 40 15.69% 41 23.98% 4.32 0.038
Overweight 65 25.49% 46 26.90% 0.10 0.746
Obese 147 57.65% 84 49.12% 2.99 0.084
Mean SD Mean SD t p
Age 47.87 12.41 46.22 11.1 1.40 0.162
Charlson comorbidity index 0.94 1.78 1.16 1.78 −1.47 0.142
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p = .11). HRQoL was also significantly higher for patients
using aripiprazole in the domains of bodily pain scores
(56.18 vs. 48.83; p = .018, Cohen’s d = 0.24), general
health (49.92 vs. 42.95; p = .013, Cohen’s d = 0.25), andemotional role limitations (50.05 vs. 42.98, p = .012,
Cohen’s d = 0.25). Differences in mean health utility
scores were marginally significant (0.57 vs. 0.54,
p = .055), though they were above clinically-relevant
levels (i.e., greater than or equal to 0.03).
Table 2 Depression treatment history differences between patients taking aripiprazole or another atypical
antipsychotic to treat their depression
Aripiprazole (n = 255) Other atypical (n = 171)
Variable n % n % χ2 p
Psychiatrist as prescribing physician 177 69.41% 124 72.51% 0.48 0.489
Years diagnosed with depression
1 - 5 years 68 26.67% 42 24.56% 0.24 0.625
6 - 10 years 55 21.57% 43 25.15% 0.72 0.395
11 years or more 129 50.59% 84 49.12% 0.09 0.767
Concomitant treatments
SSRI 130 50.98% 103 60.23% 3.58 0.059
SNRI 111 43.53% 43 25.15% 16.23 <.0001
TCA 28 10.98% 21 12.28% 0.17 0.684
Other 85 33.33% 64 37.43% 0.75 0.388
Kalsekar et al. Health and Quality of Life Outcomes 2012, 10:81 Page 6 of 10
http://www.hqlo.com/content/10/1/81Main analysis: adjusted differences between respondents
using aripiprazole and respondents using other atypical
antipsychotics
After controlling for demographics and health character-
istic variables, the directionality of the differences were
similar to the unadjusted analysis, however the size of
the differences increased (see Figure 2). Respondents
using aripiprazole reported significantly higher adjusted
mean levels of mental component summary (MCS)
scores (34.10 vs. 31.43, p = .018). These respondents also
reported significantly greater HRQoL as measured by
the bodily pain (55.19 vs. 49.05, p = .047), general health
(50.05 vs. 43.07, p = .009), and emotional role limitation












Figure 2 Adjusted HRQoL scores of patients using aripiprazole versusadjusted mean health utility scores were also significant
(0.59 vs. 0.56, p = .042) (see Figure 3).
Although the intent of these multivariable models was
to mitigate the effect of selection biases when examining
the differences between respondents using aripiprazole
and respondents using other atypical antipsychotics, the
regression output can also provide meaningful context
for these differences (see Table 3). For brevity, only the
details of the models predicting MCS, PCS, and health
utility scores are provided.
A sensitivity analysis was conducted using a series of
hierarchical multiple regressions to determine the extent
to which the exclusion of non-significant covariates
influenced the observed effects. The findings were30 40 50 60







other atypical antipsychotics for depression. *p<.05.





Adjusted health utilities (SF-6D)
*
Figure 3 Adjusted health utility scores between patients using aripiprazole and other atypical antipsychotics. *p<.05.
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using aripiprazole reported significantly higher levels of
MCS (34.28 vs. 32.06, p = .040), bodily pain (55.86 vs.
49.31, p = .025), general health (48.84 vs. 43.07, p = .007),
and emotional role limitations (49.74 vs. 43.45, p = .007).
However, differences in health utilities (0.59 vs. 0.57,
p = .15) were not significant.
Sub-analysis: comparing respondents using aripiprazole
with respondents using individual atypical antipsychotics
In a sub-analysis, users of individual atypical antipsycho-
tics were compared with users of aripiprazole. The first
comparison was made with respondents using quetiapine.
Similar to the main analysis, aripiprazole users were sig-
nificantly more likely to be disabled (7.84% vs. 3.15%,
p = .042), retired (16.08% vs. 6.30%, p = .002), insured
(90.20% vs. 78.74%, p = .006), and using an SNRI (43.53%
vs. 24.41%, p<.001) and significantly less likely to cur-
rently smoke (32.54% vs. 47.24%, p = .006), drink alcohol
(52.94% vs. 65.35%, p = .019), and be using an SSRI
(50.98% vs. 62.20%, p = .036) than users of quetiapine. In
bivariate comparisons of HRQoL, aripiprazole users
reported significantly higher levels of MCS (34.26 vs.
31.91, p = .041), bodily pain (56.18 vs. 46.26, p = .003), gen-
eral health (49.92 vs. 43.78, p = .045), mental health (41.57
vs. 36.81, p = .048), and emotional role limitations (50.05
vs. 42.62, p = .018) than patients using quetiapine. Al-
though all other summary and domain scores were greater
among patients using aripiprazole, these differences were
not significant. After controlling for demographics and
health characteristics, aripiprazole users reported signifi-
cantly higher MCS scores (33.91 vs. 31.41, p = .047) and
bodily pain (55.06 vs. 46.53, p = .011), general health
(49.89 vs. 43.72, p = .034) and emotional role limitationdomain scores (49.29 vs. 41.60, p = .017) compared with
users of quetiapine (see Figure 4). Differences in health
utilities (see Figure 3) and other summary and domain
scores were not significant.
Small sample sizes (n= 19, 14, and 11, for olanzapine,
risperidone, and ziprasidone, respectively) prevented
meaningful comparisons with the other atypical antipsy-
chotics. Aripiprazole users did report significantly greater
general health (49.92 vs. 33.93, p = .035) than users of ris-
peridone, however, no other significant differences were
observed. In most instances, though not all, the trends
were such that higher HRQoL summary and domain
scores were observed among users of aripiprazole.Discussion
Among patients who self-reported a diagnosis of depres-
sion and were using an atypical antipsychotic as part of
combination therapy with antidepressants, this study
assessed the differences in HRQoL and health utility
scores of patients using aripiprazole compared with
patients using olanzapine, quetiapine, risperidone and
ziprasidone. The results suggest that mental summary,
general health domain and mental health domain scores
(emotional role limitations and mental health), and overall
health utilities are significantly higher among those treated
with aripiprazole relative to those treated with other atyp-
ical antipsychotics, even after adjusting for demographic
and health characteristic differences between these groups.
Interestingly, even some physical aspects (i.e., bodily pain)
were reported as significantly better for those being trea-
ted with aripiprazole. It is important to note that the dif-
ferences between the groups approached or exceeded
clinically-relevant thresholds [17,18].
Table 3 Regression estimates of all sociodemographic and depression history variables
MCS PCS Health utilities
b 95% LCL 95% UCL b 95% LCL 95% UCL b 95% LCL 95% UCL
Intercept 31.754 24.302 39.205 52.049 44.581 59.517 0.653 0.570 0.735
Aripiprazole 2.673 0.460 4.886 1.321 −0.898 3.539 0.026 0.001 0.052
Age 0.150 0.056 0.245 −0.245 −0.339 −0.150 0.000 −0.001 0.001
Male −0.569 −2.741 1.603 0.275 −1.902 2.452 −0.003 −0.028 0.023
Black −0.506 −3.859 2.847 1.756 −1.604 5.117 0.013 −0.025 0.052
Hispanic −3.834 −8.186 0.518 0.021 −4.341 4.383 −0.061 −0.111 −0.011
Other race/ethnicity 1.188 −3.335 5.712 −0.643 −5.177 3.891 0.014 −0.036 0.064
Married/living with partner −4.480 −6.856 −2.104 −0.457 −2.839 1.924 −0.023 −0.050 0.003
Midwest region −3.498 −6.645 −0.351 0.791 −2.363 3.945 −0.016 −0.051 0.018
South region −1.439 −4.409 1.532 1.666 −1.311 4.643 0.000 −0.033 0.033
West region 0.386 −2.965 3.738 1.371 −1.988 4.730 0.011 −0.027 0.049
Some college education (or higher) −0.193 −2.725 2.340 1.389 −1.150 3.927 −0.009 −0.037 0.019
Income: $25 K to< $50 K 2.076 −0.571 4.723 0.881 −1.772 3.534 0.014 −0.016 0.044
Income: $50 K to< $75 K 5.593 2.343 8.843 1.175 −2.082 4.432 0.055 0.018 0.092
Income: $75 K or more 3.687 0.110 7.265 3.558 −0.027 7.144 0.039 −0.001 0.078
Health insurance −1.798 −4.891 1.296 0.644 −2.456 3.744 −0.012 −0.047 0.023
2009 survey 0.057 −2.892 3.005 −0.302 −3.257 2.653 −0.015 −0.041 0.010
2010 survey 2.393 −0.132 4.919 −0.909 −3.441 1.622 – – –
2011 survey – – – – – – * * *
Currently smoke 0.526 −1.749 2.800 −3.891 −6.171 −1.612 −0.005 −0.031 0.020
Exercise 1–9 times a month 1.238 −1.436 3.911 0.599 −2.080 3.278 0.001 −0.028 0.031
Exercise 10+ times a month 1.811 −0.773 4.394 1.047 −1.542 3.636 −0.004 −0.035 0.026
Currently drink alcohol 0.329 −1.880 2.539 1.326 −0.889 3.541 0.021 −0.004 0.047
Overweight −0.618 −3.769 2.532 −2.452 −5.610 0.706 −0.034 −0.070 0.003
Obese −0.714 −3.565 2.138 −5.169 −8.027 −2.311 −0.055 −0.088 −0.021
Charlson comorbidity index 0.157 −0.551 0.865 −2.056 −2.766 −1.347 −0.009 −0.017 0.000
Psychiatrist as prescribing physician −2.574 −4.936 −0.212 2.735 0.368 5.101 −0.012 −0.039 0.015
Diagnosed for 6–10 years −0.006 −2.963 2.951 −0.450 −3.413 2.514 0.005 −0.028 0.039
Diagnosed 11 years or more 0.138 −2.542 2.817 −0.922 −3.607 1.763 0.001 −0.030 0.033
SSRI −2.511 −5.373 0.352 1.090 −1.778 3.959 −0.009 −0.041 0.023
SNRI −3.959 −6.979 −0.939 2.353 −0.674 5.379 −0.022 −0.056 0.012
TCA −3.710 −7.054 −0.366 −2.941 −6.292 0.410 −0.063 −0.100 −0.025
Other treatment −2.044 −4.358 0.270 0.493 −1.826 2.812 −0.027 −0.053 −0.001
Reference categories included: non-Hispanic white, Northeast region, income< $25 K, not exercising, normal BMI level, being diagnosed for less than 6 years.
*Health utilities were not available from respondents of the 2011 survey; as a result, the survey year 2010 served as the reference group in the health utilities model.
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http://www.hqlo.com/content/10/1/81The results of the current study add to the literature
by providing data on head-to-head comparisons of atyp-
ical antipsychotics which, other than meta-analyses of
clinical trial data and cost studies, are generally lacking.
Because of the lack of data, comparisons between the
HRQoL effects observed here and in the literature are
difficult to make. Overall, the MCS scores reported in
the current study were lower than those observed in
other studies: 39.0 in Lenert et al. (2000) vs. 34.26 and32.09 for aripiprazole and other atypical treatments, re-
spectively. This difference is likely due to the fact that
respondents in the current study who were being treated
with both antipsychotic and antidepressant medications
may have had greater depression severity than the aver-
age depression population as assessed by Lenert et al.
(2000) [4].
As discussed by previous reviews [7,10], limited real-
world comparative effectiveness data exist on atypical


















Figure 4 Adjusted HRQoL scores of patients using aripiprazole versus quetiapine. *p<.05.
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http://www.hqlo.com/content/10/1/81antipsychotic therapy in MDD. However, clinical trial
data generally support the findings observed here. Thase
et al. [21] found that a significant reduction in patient-
reported functional impairment, as measured by the
Sheehan Disability Scale (SDS), was observed among
patients with MDD being treated with aripiprazole when
compared with placebo [21]. Patients using aripiprazole
as augmentation treatment reported lower SDS scores
and were significantly more likely to move from ‘severe’
to ‘mild’ and from ‘moderate’ to ‘mild’ levels of impair-
ment [21]. In a meta-analysis of clinical trial data, Nel-
son and Papakostous [8] found that the efficacy (as
measured by response and remission rates) for atypical
antipsychotics in MDD was significantly greater than for
placebo treatments. Although no statistically significant
differences among the atypical antipsychotics were
observed, the pooled effects for aripiprazole were higher
than other FDA-approved atypical antipsychotics [8].
Studies using real-world data have also suggested a
benefit of aripiprazole use as augmentation therapy. A
recent study by Jing et al. (2011) suggests that pharmacy
costs for patients treated with aripiprazole are higher
but total healthcare costs are significantly lower than
other atypical antipsychotics primarily due to differences
in rates of hospitalization [22]. Further, when comparing
FDA-approved atypical antipsychotics with antidepres-
sant monotherapy, aripiprazole had the lowest additional
costs per additional responder [23].
Limitations
Several limitations should be noted from the results of this
study. One of the most important limitations is that of se-
lection bias. Although real-world comparative effective-
ness data is needed, the disadvantage of such data is that
treatments are not randomized. There are likely many fac-
tors (e.g., patient characteristics, patient preferences,disease history, etc.) that may have led to the prescription
of one atypical antipsychotic over another. These factors
may also influence HRQoL. Although an attempt was
made to adjust for these differences (prescribing physician,
concomitant treatments, years diagnosed, etc.), it is pos-
sible other factors not assessed in the analysis could ex-
plain the study’s findings. Prospective and longitudinal
designs may be beneficial in replicating the effects
observed here. It is also important to note that we pooled
all other atypical antipsychotics in the main analysis due
to small sample sizes. Future research may consider a set
of amply-powered individual comparisons to replicate the
effects observed here. Given the cross-sectional, observa-
tional design of the study, the direction of causality is un-
known. Although many alternative explanations for the
HRQoL findings have been tested and ruled out (demo-
graphics, comorbidities, etc.), it is possible that other un-
measured variables might explain the relationship
between depression treatment and the outcomes observed
here. The NHWS is a self-reported survey (including
medications) so measurement error may have been intro-
duced as it relates to overall group membership (i.e., there
was no clinical verification that patients were actually
using the medications they reported). It should also be
noted that although the NHWS is demographically repre-
sentative of the overall US adult population, the sample in
the current study was restricted by several criteria. It is
unknown how the current sample generalizes to the over-
all MDD population of interest.
Conclusion
In summary, this study addresses a gap in the knowledge
of atypical antipsychotic use as augmentation therapy of
patients with MDD. The study results suggest patients
taking aripiprazole in combination with an antidepressant
in a real-world environment have a statistically and
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http://www.hqlo.com/content/10/1/81clinically meaningfully higher level of mental quality of life
and health utilities than patients taking other atypical anti-
psychotics in combination with an antidepressant. Al-
though much more research is necessary, particularly
utilizing longitudinal designs, this study provides prelim-
inary head-to-head evidence of atypical antipsychotics.
These results may help inform real-world effectiveness of
these treatments and, as patient outcomes are a valuable
part of broader disease management, inform treatment
decision making.
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